CD14 and rheumatoid arthritis: The observed predictive value of the absolute number of circulating monocytes, and of the numbers of CD14+highCD16−, CD14+highCD16+ and CD14+lowCD16+ subset cells, in terms of clinical response to MTX treatment in treatment-naive patients with RA requires confirmation in large multicenter studies including patients of different race.